Author | Salvatore Siena, MD


Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01

June 29, 2020


Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.